Q-omics provides the consensus-scored ANKRD30BP2 profile across patient tissues and cancer cell-line models. ANKRD30BP2 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ANKRD30BP2 is differentially expressed in 2, with the highest sampling consensus in LIHC. Additionally, ANKRD30BP2 RNA expression shows 6,214 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight KIRC, LIHC, and STAD as cancer lineages where ANKRD30BP2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ANKRD30BP2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ANKRD30BP2 survival associations across molecular data types. ANKRD30BP2 RNA expression shows survival associations in the most cancer types (17), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ANKRD30BP2 RNA expression–survival associations across cancer types. High ANKRD30BP2 expression shows unfavorable associations in KIRC, THYM, KIRP and READ, but favorable associations in DLBC and UCEC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ANKRD30BP2 RNA expression.
This table summarizes ANKRD30BP2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for ANKRD30BP2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ANKRD30BP2 shows higher tumor expression in LIHC and BRCA. The LIHC box plot shows higher ANKRD30BP2 RNA expression in tumor versus normal tissue (log2 FC = +0.016, t-test p = .016).
This table shows molecular features associated with ANKRD30BP2 in patient tissues and cancer cell lines. In patient samples, ANKRD30BP2 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
